Further research is warranted to elucidate the full therapeutic potential of GLP-1 RAs in AS but like many genetic kidney diseases, Alport syndrome patients have been excluded from important clinical trials exploring therapeutics that slow the progression of CKD. Here, GLP1R is linked to Alport syndrome.